This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Investigations during the last 10 years have revealed a group of disorders mediated by antibodies against ion channels and synaptic receptors, which cause both neurologic and psychiatric symptoms. In this review, I discuss the process of discovery and immunologic triggers of these disorders, and use anti-NMDA receptor encephalitis to emphasize the importance of understanding the underlying physiopathologic mechanisms in those diseases. A better knowledge of these mechanisms reveals points of convergence with other disorders (e.g., schizophrenia), suggests treatment strategies beyond immunotherapy, and is helping us understand how memories are formed and retrieved.
GLOSSARY
- BBB=
- blood–brain barrier;
- EphB2=
- Ephrin type B2 receptor;
- FLAIR=
- fluid-attenuated inversion recovery;
- HSE=
- herpes simplex encephalitis;
- IgG=
- immunoglobulin G;
- LEMS=
- Lambert-Eaton myasthenic syndrome;
- LTP=
- long-term potentiation;
- NMDAR=
- NMDA receptor
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the author, if any, are provided at the end of the article.
- Received July 10, 2016.
- Accepted in final form September 6, 2016.
- © 2016 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- GLOSSARY
- THE PROCESS OF DISCOVERY
- A HUMAN MODEL OF IMMUNE DEPLETION OF NMDAR
- TRIGGERS OF SYNAPTIC AUTOIMMUNITY: TUMORS AND VIRUSES
- ANTIBODY EFFECTS ON SYNAPSES, PLASTICITY, AND BEHAVIOR: IMPLICATIONS FOR THERAPIES
- ANTI-NMDAR ENCEPHALITIS AND THE NMDAR HYPOFUNCTION MODEL OF SCHIZOPHRENIA: TWO MECHANISMS CONVERGING ON NMDAR NETWORKS
- FUTURE STUDIES: AUTOANTIBODIES TO EXPLORE BRAIN FUNCTION
- AUTHOR CONTRIBUTIONS
- STUDY FUNDING
- DISCLOSURE
- ACKNOWLEDGMENT
- Footnotes
- REFERENCES
- Figures & Data
- Info & Disclosures
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard